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Conclusions: Low viable count of P. aeruginosa cough aerosols and a lack of shared P. aeruginosa strains observed suggesting that aerosol transmission of P. aeruginosa is an unlikely mode of respiratory infection spread in people with bronchiectasis and COPD. Pseudomonas aeruginosa is an opportunistic pathogen isolated from the sputum of people 4 with underlying lung conditions. In people with cystic fibrosis (CF) over 12 years of age, P. 5 aeruginosa is the dominant bacterial pathogen 1 and cross-infection between people with CF 6 attending specialist centres has been well-documented. 2, 3 The transmission route of 7 P. aeruginosa cross-infection has been suggested as aerosol transmission with evidence that 8 viable P. aeruginosa (and other CF pathogens) cough aerosols could travel for four metres 9 from the source (person with CF) and remain in the air for 45-minutes after cough 4, 5 . Yet, 10 shared strains of P. aeruginosa have not been found in environmental sampling, 6 further 11 supporting aerosol transmission as a possible mode of cross-infection. 12 
13
In (non-CF) bronchiectasis and chronic obstructive pulmonary disease (COPD), 14 P. aeruginosa predominantly causes infection in those with severe disease 7, 8 and is 15 associated with poorer prognosis 9 , higher mortality [10] [11] [12] and increased hospital admissions 13 .
16
Yet unlike CF, cross-infection with P. aeruginosa is reported to be uncommon in people 17 with bronchiectasis and COPD. [14] [15] [16] [17] [18] [19] [20] 
Aerosol study 42

Cough aerosol sampling 43
Twenty participants with bronchiectasis (n=16) or COPD (n=4) underwent cough aerosol 44 testing using two validated cough rigs -"distance" and "duration" rigs. 4, 22 Participants 45 performed up to five cough tests: two tests in the distance rig with aerosol collection points 46 at 2-and 4-metres (order randomised), and three tests in the duration rig with aerosol ageing 47 periods of 5-, 15-and 45-minutes. The distance and duration testing methodology have been 48 described in detail previously with participants monitored by a healthcare professional. 4, 5, 22 
49
In brief, participants performed respiratory function testing on the day of testing to measure 50 forced expiratory volume in one-second (FEV1) and forced vital capacity (FVC) according 51 to ATS guidelines. 23 Weight, height and age were recorded and the percent predicted values 52 calculated from the Global Lung Index. 24 
54
Distance testing 55
For each cough test (2-and 4-metres), participants entered into the "distance" rig, completed 56 2-minutes of tidal breathing to purge the lungs of room air and then proceeded to cough for 57 5-minutes at a comfortable pace determined by each study participant. Cough aerosols were 58 extracted continuously during this time using an Andersen Cascade Impactor (ACI) (Thermo 59
Fisher Scientific, USA). The ACI for both distance and duration testing (see below) was 60 loaded with Chocolate-Bacitracin media (300 µg/mL) to determine the viability of P. 61 aeruginosa in cough aerosols. 4 
63
Duration testing 64
Participants with COPD were excluded from the duration testing due to airflow obstruction 65 severity. For each test, the remaining bronchiectasis participants completed 2-minutes of 66 tidal breathing to purge the lungs of room air followed by coughing for 2-minutes at a 67 comfortable pace determined by each study participant. The cough aerosols were sealed in 68 the rotating drum inside the duration rig, aged (5-, 15-or 45-minutes) and then extracted 69 using an ACI as previously described. Qualitative and quantitative sputum cultures were performed. 4, 5 The aerosol agar plates were 73 incubated aerobically at 37 °C for 72-hours. Presumptive identification of 74 P. aeruginosa isolates was based on positive oxidase reaction and growth at 42 °C. All 75 bacterial isolates had confirmatory identification using matrix-assisted laser 76 desorption/ionisation-time-of-flight (MALDI-TOF) mass spectrometry and real-time 77 PCR. 25 Sputum and aerosol P. aeruginosa colony forming units (CFU) for individual 78 P. aeruginosa morphotypes were enumerated. The total viable count in sputum (CFU/mL) 79 and total bacterial species aerosol count across the six-stages of the ACI were determined. 80
Participants were defined as low (<10 total aerosol CFU) or high (≥10 total aerosol CFU 81 count) aerosol producers. 26 A hole-correction factor was applied to account for possible 82 'stacking' of bacterial colonies on the agar plates inside the ACI. 27 All confirmed 83 P. aeruginosa isolates underwent genotyping using an iPLEX20SNP assay (Sequenom) for 84 genotyping as previously published. subsequently confirmed by real-time PCR. 25 All confirmed P. aeruginosa isolates 98 underwent iPLEX20SNP genotyping. 28 The genotyping results were evaluated using a 99 database of multilocus sequence profiles from local environmental, animal, CF and non-CF 100 associated clinical isolates. 6, 28 Fourteen isolates (from nine participants) had 101 deviation. The total CFU count present in both sputum and aerosols were log transformed 119 and reported as geometric mean and 95% confidence interval (CI). The Jeffreys 95% CI is 120
given for the proportion of participants with P aeruginosa detected in cough aerosols. A 121 two-tailed Pearson's correlation was used to examine the correlation between the mean 122 concentration of P. aeruginosa in the sputum and total mean P. aeruginosa aerosol count at 123 2-metre testing. A linear mixed effect model with participant as the random effect and cough 124 test as a fixed effect was used to calculate the overall mean and 95% CI for the total mean 125 count of Gram-negative bacteria other than P. aeruginosa. Values presented in Table 1 cough aerosols containing P. aeruginosa during at least one cough tests (Table 2 ) and also 148 had P. aeruginosa detected their sputum sample provided on the day of testing. P. 149 aeruginosa positive aerosols were detected in 5/20 (25%) participants (bronchiectasis, n=4; 150 (13%) bronchiectasis participants only at 15-minutes (Table 2 ). All participants were 152 considered as low producers 26 of P. aeruginosa cough aerosols with a total mean aerosol 153 count of 2 CFU at 2-metres (n=5), 3 CFU at 4-metres (n=4), and 1 CFU at 15-minutes (n=2) 154 ( The three participants that cultured other Gram-negative bacteria from the sputum also had 176 these bacteria recovered from ≥3 of their cough aerosols samples (H. influenzae, n=2; 177 E. coli, n=1; S. maltophilia, n=1; Table S1 , Supplementary Information); including one 178 participant who also produced cough aerosols with P. aeruginosa (Table S1, Supplementary  179 Information). One COPD participant did not provide a sputum sample yet produced 180
Citrobacter koseri and Achromobacter spp. in the cough aerosol samples (Table S1 , 181
Supplementary Information). The total mean aerosol count of other Gram-negative bacteria 182 from all distance and duration cough aerosol tests (total=19) was 22 (95% CI 2 -181). 183
184
Genotyping Study 185
Sputum collection 186
Sixteen (53%) of the 30 participants provided a single sputum sample. Fourteen (47%) 187 participants provided multiple sputum samples (two, n=10 participants or three, n=4 188 participants) and the median duration between the initial and final samples was 8. Our study demonstrates that people with bronchiectasis and COPD can release aerosols 219 containing viable P. aeruginosa during coughing; however, no shared strains of 220 P. aeruginosa respiratory infection were detected in study participants. Our results support 221 the published data that cross-infection of P. aeruginosa affects a minority of people with 222 bronchiectasis [14] [15] [16] and provides much needed evidence to understanding cross-infection in 223 bronchiectasis, which was highlighted as a research priority in a recent review. 30 Whilst we 224 have demonstrated that aerosol transmission is an unlikely transmission route, it is worth 225 noting that the participants selected for the study were all low producers 26 of 226 P. aeruginosa cough aerosols and also, that the study participants had very few opportunities 227 for transmission events to occur during hospital visits; thus reducing the risk of potentially 228 being exposed to each other's cough aerosols. 229
230
The results of our cough aerosol study were in contrast to the results of previous studies in 231 people with CF (Table 2 ) despite that the participant numbers were almost the same (CF 232 cough study, n=19 4 versus this study, n=20). Firstly, only 25% of all participants in this 233 study produced cough aerosols containing viable P. aeruginosa at two-metres whereas most 234 participants with CF produced cough aerosols containing P. aeruginosa at the same 235 distance. 4 Secondly, the total mean P. aeruginosa aerosol count at 2-metres was much lower 236 in participants with bronchiectasis or COPD compared to people with CF (2 CFU versus 39 237 CFU, respectively) ( Table 2) . 4 Thirdly, the distance that viable P. aeruginosa cough aerosols 238 could travel in people with bronchiectasis, COPD or CF 4 were similar (four-metres); 239 however, the duration that P. aeruginosa cough aerosols could remain suspended in the air 240 was shorter in people with bronchiectasis at 15-minutes compared to 45-minutes for people 241 with CF. 4 Lastly, the mean concentration of P. aeruginosa in sputum in the bronchiectasis 242 and COPD cohort did not correlate with the total aerosol count observed at two-metres and 243 this was in contrast to our findings in the CF cough aerosol studies. 4, 5, 31 244 245 Our genotyping study is the first Australian study to investigate the possibility of cross-246 infection in people with bronchiectasis and COPD attending a facility which has shared 247 inpatient and outpatient facilities with CF. Our results found that no major Australian CF 248 shared P. aeruginosa strains 33 were detected in our current cohort. In fact, our study found 249 no evidence of shared P. aeruginosa strain infections, which is in keeping with the published 250 data that shared P. aeruginosa strains are uncommon in people with bronchiectasis or 251 COPD. [14] [15] [16] [17] 19, 20 The P. aeruginosa strains detected in our study are commonly found in other 252 niches such as the natural environment and non-CF infections. 3, 6, 14, 34 Our longitudinal 253 analysis of P. aeruginosa isolates showed that the majority of participants retained the same 254 unique P. aeruginosa strain over time which is consistent with other recent 255 studies. 15, 17, 19, 20, 35 These results suggest that person-to-person transmission of P. aeruginosa 256 is unlikely to occur in people with bronchiectasis and COPD. Instead, P. aeruginosa 257 respiratory infection is likely acquired from the natural environment. 258 259 Interestingly, our study found four of the 20 participants produced cough aerosols containing 260 other Gram-negative bacteria. This was a higher proportion than in our previous CF P. 261 aeruginosa cough aerosol studies 4, 31, 32 which is likely to be related to the difference in 262 infection profile in people with bronchiectasis and COPD compared with CF populations. 263
Incidentally, we found two study participants with bronchiectasis who were high producers 264 of H. influenzae cough aerosols, 26 a common respiratory pathogen of people with 265 bronchiectasis and COPD. [36] [37] [38] [39] [40] Whilst H. influenzae cross-infection is not thought to occur 266 in people with bronchiectasis, 18 it has been recently reported in a single study of people with 267 CF; 41 though it is presently unclear if aerosol transmission plays a role in H. influenzae 268 acquisition. Our study reported one non-expectorating participant with COPD who produced 269 cough aerosols containing C. koseri and Achromobacter spp. The finding of potentially 270 infectious cough aerosols in the absence of sputum production was also reported in our 271 earlier cough studies in people with CF 4,42 yet was in contrast to our two most recent studies 272 in people with CF which found that people with CF who could not expectorate sputum were 273 unable to generate potentially infectious cough aerosols. 31, 32 274 275 This study had several limitations. Firstly, most people with COPD and P. aeruginosa 276 respiratory infection were unsuitable for participation because they had severe airflow 277 obstruction which impacts on the generalisability of our results in these patients. Therefore, 278 a larger study using altered study protocols may better include participants with COPD and 279 may support stronger correlations between clinical and microbiological measures and 280 aerosol CFU counts. Secondly, our sample size was small and the number of participants 281 which produced viable P. aeruginosa in their cough aerosols was low. Therefore robust 282
estimates cannot be determined however, the estimates obtained in this study are useful for 283 calculation of sample size for future cough aerosol studies. Similarly, given that the number 284 of participants in the Genotype Study had a median follow-up time of less than 12 months, 285 the diversity of genetic variation of P. aeruginosa in patients with bronchiectasis may have 286 also been underestimated. Thirdly, the infectious dose of 287 P. aeruginosa and other Gram-negative bacteria is not known and therefore, the risk of 288 infection from exposure to potentially infectious aerosols remains uncertain. Fourthly, the 289 study participants were tested when clinically stable and therefore, may underestimate the 290 P. aeruginosa aerosols released during pulmonary exacerbations. Fifthly, the media used to 291 capture the cough aerosols was selective for Gram-negative bacteria and thus, the results of 292 this study cannot be generalised to those people with bronchiectasis and COPD harbouring 293
Gram-positive bacterial respiratory infections. Finally, the longitudinal analyses, at times, 294 included one isolate per sputum which limited the capacity to detect strain diversity. 295
296
Our study has demonstrated that people with bronchiectasis and COPD can release low 297 amounts of viable P. aeruginosa aerosols during coughing. The result confirms the finding 298 that P. aeruginosa cross-infection is uncommon in bronchiectasis and that aerosol 299 transmission seems unlikely to be a major contributor to P. aeruginosa cross-infection. 300 301 Never, n (%) 2 # /4 (50%) 1/1 (100%) Former, n (%) 2/4 (50) n/a -Pack years, median (IQR) (45, 85)~ n/a *n=13 also participated in the Aerosol Study; ^n =28; ~i ndividual pack years; # One COPD participant had alpha-1 antitrypsin deficiency and the other COPD participant had longstanding asthma); n/a, not applicable. 
